The FDA on July 11, 2017 approved BLINCYTO® for the treatment of relapsed or refractory B-cell precursor Acute Lymphoblastic Leukemia (ALL) in adults and children. BLINCYTO® is a product of Amgen Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
